Amarin Still Suspends FY22 Guidance On Generic Challenges
Amarin Corporation plc (NASDAQ:AMRN) continues suspending 2022 revenue guidance citing the ongoing global impact of COVID-19, the uncertainty resulting from the…
AmerisourceBergen Boosts FY22 Profit Outlook As Q3 Beat Expectations
AmerisourceBergen Corp’s (NYSE:ABC) Q3 FY22 adjusted EPS reached $2.62, up 21.3% Y/Y, beating the consensus of $2.57. Revenue of $60.1…
Regeneron’s Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $9.77 per share for Q2 FY22, down 62% Y/Y, beating the $9.54 estimate. Sales decreased…
Merrimack Pharma-Ipsen’s Cancer Drug Fails In Overall Survival Measure
Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK) partner announced that Ipsen SA (OTC:IPSEY) reported a primary analysis of the results of the…
Horizon Therapeutics’ Shares Tumble On Q2 Miss, Trimmed FY22 Outlook
Horizon Therapeutics plc’s (NASDAQ:HZNP) reported Q2 sales of $876.4 million, +5% Y/Y, missing the consensus of $936.10 million. The adjusted…
Kiniksa Inks Global License Agreement With Roche For Vixarelimab
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has announced a global license agreement with Roche Holdings AG (OTC:RHHBY) and Genentech to develop and commercialize vixarelimab, a fully human…
Merck’s Two Keytruda Combo Cancer Trials Miss Primary Goal
Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy (docetaxel) did not meet its dual…
CVS Health Q2 Sales Up Across Insurance & Pharmacy, Lifts Annual Outlook
CVS Health Corp’s (NYSE:CVS) Q2 sales increased 11% Y/Y to $80.6 billion, beating the consensus of $76.37 billion. Prescriptions filled…
Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance
Axonics Inc (NASDAQ:AXNX) reported a 50% Y/Y increase in Q2 sales to $69 million, beating the consensus of $59 million.…
Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus
Emergent BioSolutions Inc’s (NYSE: EBS) Q2 sales fell 39% Y/Y to $242.7 million, missing the consensus of $270.94 million. Revenues from…